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Abstract: MicroRNAs (miRNAs), a group of small non-coding RNAs that fine tune 
translation of multiple target mRNAs, are emerging as key regulators in cardiovascular 
development and disease. MiRNAs are involved in cardiac hypertrophy, heart failure and 
remodeling following cardiac infarction; however, miRNAs involved in hypertension have 
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not been thoroughly investigated. We have recently reported that specific miRNAs play an 
integral role in Angiotensin II receptor (AT1R) signaling, especially after activation of the 
Gαq signaling pathway. Since AT1R blockers are widely used to treat hypertension, we 
undertook a detailed analysis of potential miRNAs involved in Angiotensin II (AngII) 
mediated hypertension in rats and hypertensive patients, using miRNA microarray and 
qPCR analysis. The miR-132 and miR-212 are highly increased in the heart, aortic wall 
and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following 
chronic AngII infusion. In addition, activation of the endothelin receptor, another Gαq 
coupled receptor, also increased miR-132 and miR-212. We sought to extend these 
observations using human samples by reasoning that AT1R blockers may decrease  
miR-132 and miR-212. We analyzed tissue samples of mammary artery obtained from 
surplus arterial tissue after coronary bypass operations. Indeed, we found a decrease in 
expression levels of miR-132 and miR-212 in human arteries from bypass-operated 
patients treated with AT1R blockers, whereas treatment with β-blockers had no effect. 
Taken together, these data suggest that miR-132 and miR-212 are involved in AngII 
induced hypertension, providing a new perspective in hypertensive disease mechanisms.  
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1. Introduction 
Persistent elevation of systemic blood pressure (hypertension) is one of the most prevalent medical 
conditions involving the cardiovascular system and affects as many as one billion people  
worldwide [1]. Hypertension is an undisputed risk factor for cardiovascular diseases, including stroke, 
cardiac failure and renal diseases [1]. Several mechanisms have been implicated in the pathogenesis of 
hypertension, including increased activity of the sympathetic nervous system, dysfunction of the 
vascular endothelium, vascular smooth muscle and cardiac hypertrophy, as well as overactivation of 
the renin-angiotensin-aldosterone system (RAAS) [2]. Angiotensin II (AngII) controls blood pressure 
and fluid homeostasis through its receptors, AT1R and AT2R, and through stimulation of  
aldosterone [1]. AngII receptors are expressed in tissues that have an impact on blood pressure control, 
including heart, kidney and vasculature [3,4]. The classical AngII responses in the cardiovascular and 
renal systems are mediated mainly by AT1R signaling [3–5], including heterotrimeric G-protein 
activation and downstream signaling through the canonical MAP kinases ERK1/2, which, in turn, 
regulate gene transcription [4]. Accordingly, specific inhibitors of AngII pathways, including AT1R 
blockers, dramatically lower blood pressure in hypertensive patients and slow the progression of 
cardiovascular disease [1,3].  
We speculated that altered expression of microRNAs (miRNA) may be part of the pathogenesis 
behind AngII-related hypertension. MicroRNAs are small non-coding RNAs that regulate gene 
expression by pairing to and destabilizing the mRNAs of protein coding genes, resulting in decreased 
mRNA levels [6]. The mammalian miRNAs are highly conserved, and each miRNA is predicted to 
target mRNAs of hundreds of distinct genes, fine-tuning and optimizing the expression patterns of 
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most protein-coding genes [7]. Theoretically, these miRNAs are ideally suited to co-regulate gene 
expression events in cellular responses to vasopressors, such as AngII. Most miRNAs are solitary and 
expressed under the control of their own promoters and regulatory sequences, while others are 
arranged as clusters and may be co-regulated with additional members of the cluster [7]. For example, 
miR-132 and miR-212 are clustered closely in the genome and are transcribed together under the 
regulation of cAMP response element binding protein [8], which is a known AngII regulated  
gene [9,10]. Several miRNAs are aberrantly expressed in cardiovascular diseases [2,11–13]. miR-21, 
miR-155 and miR-221/222 have recently been shown to regulate AngII signaling in cardiac  
fibroblasts [14–16] and in endothelial cells [17], while miR-29 regulates fibrotic pathways [18]. We 
have recently shown that AngII, via the Gαq pathway, regulates five miRNAs during in vitro stimulation 
of primary cardiac fibroblasts and of HEK293N cells overexpressing the AT1-receptor [19]. Most of 
the miRNA studies are based on in vitro experiments, and very few studies have examined the relation 
between AngII mediated hypertension and miRNA regulation in vivo. 
In this study, we hypothesized that in vivo AngII mimics the “five miRNA” expression signature 
obtained by AT1R overexpression [19]. We examined the miRNA expression in heart, aorta and 
kidney from a rat model with a constant intravenous infusion of AngII and expanded these results to 
data concerning miRNA expression in the mammary artery of patients treated with AT1R blockers. 
Our results suggest that miR-132 and miR-212 are involved in AngII-induced Gαq-signaling pathway 
leading to hypertension. Further understanding of the importance of these miRNAs will come from 
future miRNA knockdown experiments or knockout in whole animals. 
2. Results 
2.1. High Blood Pressure, Cardiac Hypertrophy and Fibrosis Are Sustained in the Rat Model  
Infusion of AngII for 10 days resulted in a stable and significant elevation in blood pressure to  
159 ± 12 mm Hg (p < 0.001, n = 7) at day 10, as compared to control rats that remained constant at  
98 ± 4 mm Hg (n = 8) (Figure 1A). Likewise, we found that short time (4 h) AngII infusion resulted in 
an acute and significant 29 mm Hg increase in blood pressure (p < 0.001, n = 6) (Figure 1B). AngII 
hypertensive rats exhibited cardiac hypertrophy, as evidenced by a significant 17% increased left 
ventricle to body weight ratio (p < 0.01, n = 7) versus control rats (n = 6) (Figure 1C). The mass of the 
left ventricle increased from 614 ± 82 mg (n = 6) in control rats to 780 ± 75 mg (n = 7) in the 
hypertensive rats (p < 0.01), whereas no increase was observed for the right ventricle or atria weight 
(Figure 1C). Left ventricular hypertrophy was further validated by a significantly higher expression 
level of B-type natriuretic peptide (BNP) (p < 0.001) (Figure 1E). Likewise, cardiac fibrosis after 
infusion of AngII for 10 days was confirmed by increased collagen deposition (Figure 1D) and an 
increased expression of genes generally associated with fibrosis, including Fibronectin (p < 0.01) and 
Procollagen I (p < 0.001) (Figure 1E). These results thus showed that continuous AngII infusion for  
10 days resulted in clear and sustained hypertension, leading to hypertrophic and fibrotic changes of 
the heart. 
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Figure 1. Characterization of AngII-induced hypertensive rat. (A) Mean daily averages of 
mean arterial blood pressure from seven rats treated with chronic infusion of 30 ng/kg/min 
AngII for 10 days (□) and six rats treated with acute infusion of 30 ng/kg/min AngII for  
4 h (∆), compared to eight control rats (Ο); (B) Mean hourly averages of mean arterial 
blood pressure from acute infusion of rats (∆) for four h compared to control rats (Ο). Data 
are shown as the mean ± SD. Arrows shows the start of AngII infusion (day 0). Statistical 
significance was tested by two-way ANOVA for either control versus AngII for 10 days or 
control versus AngII for 4 h. *** p < 0.001. A and B, duplicate figure [20]; (C) Weight to 
body weight ratio (mg/g) of chronic (n = 7), acute (n = 6) and control (n = 8) rat hearts 
divided into left ventricle, right ventricle and atria. Data is presented as the  
mean ± SD, and statistical significance was tested by one-way ANOVA using Tukey’s 
multiple comparison test. ** p < 0.01; (D) Representative sections of left ventricles of 
AngII affected hearts compared to control hearts, stained with Sirius Red for collagen 
deposition; (E) qRT-PCR for the early marker of hypertrophy, BNP, the fibrotic markers, 
Fibronectin and Procollagen-I, and the two stably expressed reference genes, Gapdh and 
Rpl13a (M: 0.140 and CV: 0.049). Data is presented as the mean ± SD, and statistical 
significance was tested by un-paired t-test. * p < 0.05, ** p < 0.01 and *** p < 0.001.  
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2.2. Chronic AngII-Mediated Hypertension in Rats Increases miR-132/-212 Cluster Expression in 
Blood Pressure Regulating Organs: Heart, Aorta and Kidney  
Table 1. miRNA microarray analysis showing significantly altered miRNA expression in 
the left ventricles from rats infused with AngII for 10 days compared to controls. Data is 
presented as log2 fold expression (n = 6–7) and sorted by p-value. 
Microarray: miRNAs regulated by AngII 
Name of miRNA Log fold change p-value 
  *** p < 0.001 
21 0.7016 1.89 × 10−5 
132 0.1261 5.90 × 10−5 
105 0.1883 9.28 × 10−5 
155 0.1425 0.00012 
221 0.3414 0.00052 
223 0.4459 0.00085 
208b 0.5560 0.00089 
  ** p < 0.01 
222 0.1681 0.0022 
147b 0.1151 0.0032 
26b −0.1153 0.0034 
15b 0.2580 0.0057 
613 −0.1047 0.0065 
31 * 0.1054 0.0075 
520b 0.0938 0.0082 
30c-1 * −0.1409 0.0084 
18b 0.1334 0.0092 
  * p < 0.05 
301a 0.1537 0.010 
143 0.1242 0.011 
434-5p 0.1692 0.012 
484 0.0855 0.014 
155 0.1135 0.014 
379 0.0813 0.015 
29c −0.2193 0.017 
936 0.1682 0.018 
199a-5p 0.1523 0.021 
201 −0.1204 0.021 
101 −0.1860 0.021 
363 * 0.2352 0.021 
760 −0.0944 0.022 
944 0.1056 0.023 
200b * 0.1079 0.024 
30b −0.0888 0.025 
322 −0.1890 0.026 
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Table 1. Cont. 
Microarray: miRNAs regulated by AngII 
Name of miRNA Log fold change p-value 
337-3p 0.1065 0.026 
29c * −0.1247 0.028 
302c * 0.1453 0.030 
193a-3p 0.1665 0.030 
888 −0.0852 0.033 
299-3p 0.2128 0.035 
142-3p 0.3121 0.035 
517 * 0.0746 0.041 
31 0.3286 0.042 
194 −0.0860 0.042 
701 0.0671 0.042 
545 −0.0834 0.043 
609 0.0617 0.044 
141 * −0.0928 0.045 
211 0.0588 0.047 
373 0.0712 0.048 
218-1 * −0.0678 0.049 
* means the passenger strand of the miRNA-miRNA* duplex; Passenger miRNA, may also have constitute a 
bioactive miRNA itself.  
Fifty miRNAs were identified as differentially expressed (p < 0.05) in hearts of sustained 
hypertension (10 days of AngII), as compared to controls (Table 1), whereas no miRNAs were 
differentially expressed in acute hypertensive rats (4 h of AngII). AngII affects the blood pressure by 
two separate mechanisms: firstly, an acute contractile effect on the arterial walls arising within a few 
hours, followed by a chronic compensative response arising after a few days. Gene expression is 
primarily effected by the long-term AngII signaling. However, we sought to investigate if miRNAs 
could rapidly change, due to the acute effect, and found no regulation of miRNAs in the short period of 
AngII infusion. Of the 50 miRNAs differentially regulated in chronic hypertension, miR-21 was the 
most upregulated and was used as a positive control in our analysis. Interestingly, among the many 
dysregulated miRNAs, the second most significantly regulated miRNA was miR-132. Since the  
miR-132 gene is clustered with the miR-212 gene and they are likely expressed together [21], we 
included miR-212 in further analyses. In summary, we found that the expression of miR-21, -132 and  
-212 were up-regulated by 3.4-, 1.4- and 1.8-fold, respectively, in the left ventricle of AngII-induced 
hypertensive animals, as compared to controls (Figures 2A and S1). Besides the heart, the arterial wall 
and kidneys are involved in systemic blood pressure homeostasis, and we, therefore, examined 
whether the miR-132/-212 levels were affected also in these tissues. miR-132 and -212 were increased 
6.4- and 3.2-fold, respectively, in aortas from hypertensive animals, as compared to controls  
(Figure 2A). Likewise, we observed a significant regulation of miR-132 (1.4-fold) and -212 (1.5-fold) 
in the kidneys of AngII-infused rats versus controls (Figure 2A). Furthermore, miR-132 was found to 
be significantly upregulated in the plasma of AngII-induced hypertensive animals, whereas no 
regulation was observed for plasma miR-212 levels compared to the control rats (Figure 2B). Lack of 
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miR-212 upregulation in the plasma of AngII-induced hypertensive rats compared to control rats might 
be caused by the low concentration and high variability of the miR-212 levels found in the plasma. Of 
note, the miRNA expression levels were found to significantly correlate with AngII-induced 
hypertension in the kidneys, a strong tendency of correlation in aorta and a lower tendency for 
correlation in the heart as tested by linear regression and correlation analysis (Figure 2C). By contrast, 
no changes in miR-132/-212 levels were found in any of the three tissues in the acutely hypertensive 
rats (Figure 2A). These data confirmed the microRNA array data obtained for chronic and acute 
hypertensive rats. Altogether, these results strongly suggest that the miR-132/-212 cluster may be a 
general and novel mediator of AngII-induced hypertension. 
Figure 2. Validation of miRNA regulation in AngII-induced hypertensive rat heart, aorta 
and kidney. (A) qRT-PCR identification of miRNAs in left ventricle of hearts, aortas and 
kidneys from AngII affected rat hearts. Statistical significance was tested by one way 
ANOVA. * p < 0.05. Values are shown as relative expression with the mean ± SD;  
n = 4–7; (B) qRT-PCR identification of miRNAs in plasma of AngII affected rat hearts. 
Statistical significance was tested by un-paired t-test. ** p < 0.01. Values are shown as 
relative expression with the mean ± SD; n = 4–5. miRNA expression in the three organs 
and in plasma was individually normalized to two reference genes stably expressed among 
the samples. Reference genes used for normalization: Heart, miR-17 and miR-191  
(M: 0.356, CV: 0.123); aorta, miR-103 and miR-191 (M: 0.832, CV: 0.290); kidney,  
miR-17 and miR-191 (M: 0.145, CV: 0.050); and plasma, miR-17 and miR-103 (M: 1.143, 
CV: 0.390); (C) Correlation analysis for miRNA expression levels at day 10 of AngII or 
isotone glucose infusion. Statistical significance was tested by linear regression (R2) and 
correlation analysis (Pearson’s r). Data are shown as two individual correlations per 
miRNA is each organ for control (○) and AngII for 10 days (●). ** p < 0.01; n = 7–11. 
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2.3. miR-132 and -212 Regulation in Response to AngII in Mice  
Studying mice in this particular field of hypertension research is of interest, because their genome 
can easily be modified. Infusion of AngII at 15, 30 and 60 ng/kg/min for seven days resulted in a stable 
and significant elevation in blood pressure to 119 ± 10, 127 ± 5 and 128 ± 10 mm Hg (p < 0.001,  
n = 3), respectively, at day seven, as compared to control mice that remained constant at 95 ± 2 mm 
Hg (n = 4) (Figure 3A). AngII-infused mice did not exhibit cardiac hypertrophy when examining the 
left ventricle to body weight ratio (n = 3) versus control mice (n = 4) (Figure 3B). Likewise, miR-132 
and miR-212 were not significantly increased in AngII-infused mice at any of the AngII concentrations 
when compared to control mice. These results thus showed that continuous AngII infusion for seven 
days in mice resulted in a modest increase in blood pressure without hypertrophic changes of the heart 
and no regulation of the miR-132/-212 cluster. 
Figure 3. Validation of miRNA regulation in AngII-induced hypertensive mice hearts.  
(A) Mean daily averages of mean arterial blood pressure from three mice treated with 
chronic infusion of 60, 30 or 15 ng/kg/min AngII for seven days (□, ∆ or ◊, respectively), 
compared to three control mice (Ο). Data are shown as the mean ± SD. AngII infusion is 
started at day 0. Statistical significance was tested by two-way ANOVA. *** p < 0.001,  
*p < 0.05; (B) Left ventricle (LV) weight to body weight ratio (mg/g) of mice infused with 
60, 30 or 15 ng/kg/min of AngII for seven days (n = 3) and control (n = 3) mice. Data is 
presented as the mean ± SD, and statistical significance was tested by one-way ANOVA 
using Tukey’s multiple comparison test; (C) qRT-PCR identification of miRNAs in left 
ventricle of hearts from AngII affected mice hearts. Statistical significance was tested by 
one-way ANOVA using Tukey’s multiple comparison test. Values are shown as relative 
expression with the mean ± SD; n = 3. Reference genes used for normalization: miR-103 
and miR-191 (M: 0.826, CV: 0.288). 
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Figure 4. Endothelin 1-induced hypertensive rats. (A) Mean daily averages of mean 
arterial blood pressure from five rats treated with chronic infusion of 5 pmol/kg/min ET-1 
for 10 days (□), compared to three control rats (Ο). Statistical significance was tested by 
two-way ANOVA. *** p < 0.001; (B) qRT-PCR for the early hypertrophy marker, BNP 
and the fibrosis markers, Fibronectin and Procollagen-I. Statistical significance was tested 
by un-paired t-test. Data is shown as the mean ± SD, n = 3–5. Reference genes used for 
normalization: GAPDH and Rpl13a (M: 0.153, CV: 0.053); (C) qRT-PCR identification of 
miRNAs in the left ventricle of hearts, aortas and kidneys from ET-1 affected rat hearts. 
Statistical significance was tested by un-paired t-test. * p < 0.05. Values are shown as 
relative expression with the mean ± SD, n = 3–5. miRNA expression was individually 
normalized to two reference genes stably expressed among the samples. Reference genes 
used for normalization: heart; miR-17 and miR-191 (M: 0.309, CV: 0.107); aorta, miR-103 
and miR-191 (M: 0.667, CV: 0.232); kidney, miR-17 and miR-191 (M: 0.180, CV: 0.062). 
 
2.4. miR-132 and -212 Regulations in Response to ET-1, Vasopressor-Induced Hypertension 
In order to test whether the miR-132/-212 cluster response is specific for AT1R induction, we 
examined the effect of continuous infusion of a second vasopressor (ET-1) [22]. In contrast to the 
sustained high blood pressure in AngII-infused rats, ET-1-mediated hypertension peaked at day one 
(144 ± 6 mm Hg (n = 5) and, hereafter, gradually declined, reaching 105 ± 7 mm Hg at day 10  
(Figure 4A). In line with this, we did not observe any cardiac hypertrophy or fibrosis in ET-1 treated 
hearts. Thus, we found no change in BNP, Fibronectin or Procollagen-I expression levels (Figure 4B). 
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However, despite the partially compensated blood pressure and the absence of cardiac hypertrophy and 
fibrosis, we found significantly higher levels of miR-132 and miR-212 in heart (1.7- and 2.0-fold), 
aorta (3.5- and 2.5-fold) and kidney (1.5- and 1.8-fold) of the ET-1 treated animals as compared to 
controls (Figure 4C). In line with the previous findings by Jeppesen et al. [19], this suggests that the  
upregulation of miR-132/-212 is a direct consequence of Gαq vasopressor stimulation pathways and 
not a result of secondary heart hypertrophy and fibrosis. In summary, these data indicate that  
upregulation of the miR-132/-212 cluster likely is part of a general response to Gαq-vasopressor 
stimulation of the ERK1/2 pathway and may be involved in a common AngII- and ET-1-mediated 
signaling pathway leading to hypertension. 
Figure 5. AngII receptor blockers and β-blockers in internal mammary artery (IMA) 
patients. (A,C) Study group information on the AngII receptor blocker (ARB) and  
β-blocker patient groups, respectively. None of the characteristics within the patient groups 
of ARBs and β-blockers were significantly different. The groups were matched for age, 
sex, diabetes and treatment using statins. None of the patients were simultaneously treated 
with angiotensin-converting enzyme (ACE)-inhibitors; (B) Scatter plot represents Log10 
relative miRNA expression with mean bar, in patients treated with ARBs compared to 
patients treated with non-ARB (n = 16). (D) Scatter plot representing Log10 relative 
miRNA expression with mean bar, in patients treated with β-blocker (n = 9) compared to 
patients treated with non-β-blockers (n = 23). Expression is normalized to two stably 
expressed reference genes. Reference genes used for normalization: miR-103 and miR-191 
(M: 0.804, CV: 0.279). 
 
2.5. Treatment with Angiotensin II Receptor Blocker Attenuates the Expression of the miR-132/-212 
Cluster in Human Hypertension  
We measured miR-132/-212 levels in the internal mammary artery (IMA) tissue obtained from 
patients treated with AngII receptor blocker (ARB) or β-blocker in age and sex matched patients 
undergoing by-pass surgery (Figure 5A,C). The four patient groups showed similar pre-operative 
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blood pressure (Figure 5A,C). ARB treated patients (n = 16) revealed a significant attenuation of  
miR-132 expression (0.55-fold), as well as a tendency for miR-212 downregulation (0.64-fold), as 
compared to non-ARB-treated patients (miR-132; 0.93 and miR-212; 1.01) (n = 16) (Figure 5B). To 
further investigate whether this miR-132 and -212 regulation is specific to AngII or related to putative 
direct influences from blood pressure, we examined patients treated with β-blockers (Figure 5C). 
Interestingly, we did not find any attenuation or downregulation of miR-132/-212 expression in IMA 
patients receiving β-blockers, as compared to non-β-blocker-treated patients (Figure 5D), indicating 
that not all blood pressure-reducing agents can downregulate miR-132/-212 expression, which further 
supports the notion that AngII mediates a global upregulation of miR-132/-212 in humans. These 
results suggest that the miR-132/-212 cluster in humans may also be part of the response to  
Gαq-vasopressors, such as AngII. 
3. Discussion 
We found increased expression of miR-132 and -212 in the left ventricle, aorta and kidney, as well 
as in the plasma (Figure 2) after 10 days of sustained AngII-induced hypertension in rats, which is 
compatible with our pervious published in vitro study [19]. Even though miR-132 and miR-212 are 
expressed from the same precursor, we observed independent regulation in the different tissues in 
response to the same AngII infusion. This could be due to differences in stability and degradation [21,23]. 
Moreover, the degree of miR-132/-212 increase shows a tendency to correlate with blood pressure 
suggesting that these miRNAs could play a novel role in AT1 receptor pharmacology, both in vitro  
and in vivo.  
Blood pressure has previously been associated with miRNA. Recently, Nossent et al. investigated 
the association between single-nucleotide polymorphisms (SNPs) located in the miRNA binding sites 
of genes associated with Renin-AngiotensinII-system (RAS), blood pressure and myocardial infarction 
in a large population study [24]. Several SNPs located in RAS genes were associated with changes in 
blood pressure and were shown to interfere with miRNA regulation [24].  
miR-132/-212 has been described in both the central nervous and cardiovascular systems. In one 
study, miR-132 was reported to be constitutively expressed and released by pericyte progenitor cells, 
and transplantation of these cells into mice with myocardial infarction improves cardiac function 
through proangiogenic activities [25]. Several studies identify miR-132/-212 involvement in the 
central nervous system, i.e., in neuronal function and plasticity [8,21,26]. In addition, miR-132/-212 
has also been found to be involved in neovascularization, inflammation and adipocyte differentiation 
in the peripheral tissues [21,23,27]. Interestingly, miR-132/-212 was upregulated in the aortas of mice 
stimulated with AngII from osmotic pumps for 14 days, but this study did not report blood pressure 
values [28]. We performed similar studies with chronic AngII infusion in mice for seven days, 
simultaneously measuring blood pressure. In contrast to our rat infusion model, only a modest blood 
pressure increase was observed in this mice strain, and miR-132/-212 was not significantly upregulated 
in mouse hearts (Figure 3). Differences in AngII effects between rats and mice have previously been 
described by Cassis et al., stating that AngII infusion in mice has minimal effects compared to same 
doses given to rats [29]. Based on these data, we decided that the rat model was more suitable for 
studying AngII-induced miRNA changes in hypertensive animals. We previously demonstrated that 
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AT1R signaling regulates miR-132 and -212 in HEK293N cells and in primary cultures of cardiac 
fibroblasts through the Gαq dependent pathway [19]. These results were recently confirmed in primary 
cultures of rat vascular smooth muscle cells [28]. Additionally, we investigated the regulation of the 
miR-132/-212 cluster in endothelial cell lines and in primary cultures of vascular smooth muscle cells 
(VSMCs) and leukocytes and found no regulation in either of the cell types (data not shown). 
Furthermore, by inhibition of the Gαq subunit in cardiac fibroblasts, we demonstrated significant 
decreases in miR-132 and -212 expressions, pointing to Gαq protein activation as the responsible 
pathway for AngII-induced miRNA regulation in vitro [19].  
Using a different vasopressor (ET-1) that binds to the endothelin receptor and also activates  
Gαq-ERK1/2 signaling [30,31], we examined whether this receptor could regulate the miRNAs. 
Interestingly, even though the ET-1-induced hypertension had a much shorter duration than the 
sustained hypertension induced by AngII, both miR-132 and miR-212 were upregulated at a point in 
time when blood pressure was not (Figure 4). From a mechanistic point of view, these findings 
indicate that miR-132/-212, also in vivo, may be regulated through Gαq-ERK1/2 activation, which is 
one of the mutual steps in the AngII and ET-1 signaling pathways leading to hypertension [30–32]. 
Following these observations, we examined whether the increased miRNA expression levels could be 
attenuated by blocking the AngII signaling in humans (Figure 5). We examined the arterial walls from 
two different groups of patients treated with either one of several ARBs, including Losartan, 
Candesartan, Irbesartan and Telmisartan, or no ARB. These ARBs are widely used in hypertension 
treatment and have similar chemical structures, but different pharmacological properties and  
efficacy [33]. None of the patients were treated with ACE-inhibitors. Our patient groups were selected 
based on treatment with ARBs and individual ARB-types grouped and analyzed together in order to 
allow for statistical testing. Most patients in the ARB group probably suffered from hypertension; 
however, it has not been possible from the patient files to deduce who strictly fulfills the definitions of 
hypertension. Likewise, in the non-ARB group, the precise prevalence of hypertension is not known. 
Another limitation of our human observations is the lack of knowledge about the exact time point of 
medication, which could not be controlled. Despite these limitations, we observed a significant  
downregulation of miR-132, as well as a robust attenuation of miR-212 in the ARB-treated patients. 
We next asked whether treatment with β-blockers, often a first choice antihypertensive drug, would 
also decrease miR-132 and -212, following the notion that it could be reduction in blood pressure per 
se, which may alter the miRNA levels. However, the levels of miR-132/-212 were not downregulated 
in patients treated with β-blockers. This observation is compatible with the notion that alterations in 
miRNA is not only a spurious factor found in rodents or related to experimental systems in vitro, but 
that these molecules also could be suggested to play a role in the arterial wall among patients receiving 
medication that alters the activity in the AngII system. Our data indicates that AT1R control of these 
miRNAs is evolutionary conserved between rat and man. Thus, AT1R activation in rats increases  
miR-132 and miR-212, while blocking the AT1R decreases miRNA levels in humans. Since no  
anti-miR experiments have been conducted, it has not been possible to deduce the specific cause and 
effect relationship; however, the regulation of miR-132 and miR-212 is likely biological important, 
because although rats and humans share biological features in blood pressure control, they have 
multiple differences in the molecular subtypes of ion channels, receptors and signaling pathways in 
blood vessel cells. Further studies are necessary to assess the relative biological and pharmacological 
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impact of individual miR-132 and miR-212 levels on systemic blood pressure, in the heart, arterial 
wall and kidney. We speculate that the AT1R could perform these effects through Gαq and downstream 
activation of the ERK1/2 pathway and not through blood pressure or aldosterone. Three lines of evidence 
support this notion. Firstly, the effect was inhibited by the pharmacological blockade of AngII in vivo 
and Gαq and ERK1/2 in vitro [19]. Secondly, another Gαq activator (ET-1) reproduced the effects, 
while, finally, inhibiting Gs signaling with the β-adrenergic blocker had no effects on the  
miRNA levels.  
4. Experimental Section  
4.1. Animal Care  
Female Sprague-Dawley rats (8 weeks old, Taconic, Ry, Denmark) were housed in air-conditioned 
rooms with a 12 h dark-light cycle and fed standard diet (Altromin® Standard 1320, Lage, Germany) 
with free access to tap water. All rat experiments were approved by the Danish National Animal 
Experiment Inspectorate (Permission #2009/561/1753).  
4.2. Angiotensin II (AngII) Model  
Under Hypnorm/midazolam anesthesia, chronic catheters were placed in the left femoral vein and 
artery and connected to a swivel via a skin button between the scapulae, allowing the rat full  
mobility [34]. Following a 5–7 day recovery period, the arterial line was connected to a pressure 
transducer (Föhr Medical Instruments, Hessen, Germany), and data were collected continuously using 
Lab View software (National Instruments, Austin, TX, USA). The rats were infused with 5% glucose 
solution at a rate of 10 µL/kg/min with or without AngII (Sigma-Aldrich, St. Louis, MO, USA) for  
10 days. Rats were randomly divided into three groups: (1) 10 days’ continuous infusion of AngII at 
30 ng/kg/min (sustained hypertension); (2) 9 days’ and 20 h infusion with 5% glucose, followed by a 4 
h period of AngII infusion at 30 ng/kg/min (acute hypertension); and (3) 10 days’ infusion of 5% 
glucose (controls). Rats were sacrificed with an overdose of pentobarbital, then perfused with ice-cold 
sterile isotonic saline via the heart. The heart, kidney and aorta were dissected under sterile conditions. 
Hearts were carefully sectioned into atria, right ventricle and left ventricle, whereas aortas were 
cleaned from fat, as well as connective tissue, and kidneys were decapsulated.  
4.3. Endothelin 1 (ET-1) Model 
The setup was similar to that described above for the AngII model, but rats were randomly divided 
into two groups: (1) 10 days’ infusion of endothelin-1 (ET-1) (Bachem) at a concentration of  
5.0 pmol/kg/min in isotonic saline; and (2) 10 days’ infusion with isotonic saline, as previously 
described by Mortensen L.H. & Fink G.D. 1992 [35].  
4.4. Mice AngII Model 
The mice experiments were approved by the Danish National Animal Experiment Inspectorate 
(Permission #2009/561/1749). The setup was similar to that described above for the AngII rat model 
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with minor modifications as described below. Mixed gender C57/BL6 mice were anaesthetized using 
ketamine/xylazine and catheters placed in the femoral artery and vein for measurements of arterial 
blood pressure and AngII infusions, respectively. The mice recovered for five days before beginning 
the continuous measurements of mean arterial blood pressure and heart rate for seven days. Mice were 
randomly divided into four groups: (1–3) 7 days’ continuous infusion of AngII at 15, 30 and  
60 ng/kg/min respectively and (4) 7 days’ of continuous infusion with 5% glucose (controls). Mice 
were sacrificed and processed, as described above. 
4.5. Patients, Internal Mammary Artery Study 
Surplus arterial tissue was obtained from the repair vessel, i.e., the internal mammary artery (IMA), 
from patients undergoing coronary artery by-pass graft surgery at the Department of Cardiac and 
Thoracic Surgery, Odense University Hospital, Denmark. Four groups of patients were analyzed, 
based on intake or no intake of either AngII receptor blocker or β-blocker. Study population 
characteristics are described in (Figure 5A,C). As previously described [36], the intima/media of the 
artery was carefully dissected immediately after removal, frozen in liquid nitrogen and stored in the 
Odense Artery Biobank. The study was approved by the Ethical Review Board of Southern Denmark  
(No. S-20100044), and informed consent was obtained from each subject. 
4.6. Sirius Red Staining  
Fibrosis was identified by Sirius Red Staining for collagen deposits. Cryosections were equilibrated 
at room temperature for 30 min, rinsed in a mixture of NBF (37%) and ethanol (93%) for 45 s, 
rehydrated (5 min) and subsequently counterstained (15 min) with Weigert’s Iron Hematoxylin 
(Sigma-Aldrich, HT-107/109). Following a wash, sections were further incubated (60 min) with 0.1% 
Sirius red (Sigma-Aldrich, P6744) in saturated picric acid (Sigma-Aldrich, 365548) and finally washed 
twice in 99% ethanol. Sections were mounted with Pertex and analyzed by bright-field microscopy 
using a Leica DML332 equipped with a Leica DFC300F camera. 
4.7. Microarray and Data Processing 
The miRNA expression profiling was performed as two-color common reference hybridizations on 
LNA-based arrays (miRCURY LNA™ microRNA Array ready to spot probe set, Exiqon, Denmark) 
spotted in-house on CodeLink™ HD Activated slides (DHD1-0023, SurModics, Eden Prairie, MN, 
USA), according to the manufacturer’s recommendation. Samples were labeled with Hy3, and the 
common reference (pool of all samples) was labeled with Hy5, by use of miRCURY LNA microRNA 
Array Power labeling kit (208032-A, Exiqon) and hybridized for 16 h. Slides were washed (208021, 
Exiqon), scanned on an Agilent (G2565CA) Microarray scanner and analyzed by the Genepix 6.0 
software. Normalization and background correction was performed with “R” software using the “vsn” 
package (Bioconductor, open source software), and quadruplicate spots were averaged. Differential 
expression was assayed using the “limma” package (Bioconductor) by fitting the eBayes linear model 
and contrasting individual treatments with untreated controls. Log2 fold changes were calculated using 
the toptable function of the limma package. 
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4.8. mRNA and miRNA Analysis 
Relative qRT-PCR of mRNA and miRNA were performed, as previously described [37,38]. 
Briefly, total RNA was extracted using the TriReagent protocol (Molecular Research Center, Inc., 
Cincinnati, Ohio), and RNA purity, integrity and quantity were examined by nanodrop (Nanodrop® 
Technologies, Wilmington, DE, USA) and Bioanalyzer (Agilent 2100, Santa Clara, California) 
measurements. Relative quantitative mRNA PCR was performed on reverse transcribed cDNA (High 
Capacity cDNA RT kit; Applied Biosystems, Foster City, CA, USA). Primer sequences, amplification 
efficiencies (AE) and standard errors (SE): BNP forward: 5'-GATGCAGAAGCTGGAGA-3', reverse: 
5'-TCTGCTGGACCCGGAGGGTG-3', AE: 2.046 and SE: 0.011; Fibronectin forward:  
5'-CAGGGGTCACGTACCTCTTCAAAG-3', reverse: 5'-CGAGGTGGAGTCCAAGTTACCAGA-3', 
AE: 1.995 and SE: 0.010; Procollagen-I forward: 5'-ATCGTGGCTTCTCTGGTCTCCAG-3', reverse: 
5'-CAGGGAGACCGTTGAGTCCATCT-3', AE: 2.039, SE: 0.004; GAPDH forward:  
5'-GTCGGTGTGAACGGATTTGGC-3', reverse: 5'-TGAAGGGGTCGTTGATGGCA-3', AE: 2.079, 
SE: 0.008; RPL13A forward: 5'-GAAAGCGGATGAACACCAACCC-3', reverse:  
5'-GGGATCCCATCCAACACCTTGA-3', AE: 1.958, SE: 0.003. 
For miRNA qRT-PCR primers specific for rat and human miR-21 (#000397), miR-132 (#000457), 
miR-212 (#002551), miR-17 (#002308), miR-103 (#000439), miR-191 (#002299) and let-7f 
(#000382) were purchased from Applied Biosystems. Amplification and detection were performed 
using 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). As 
recommended by others [39,40] and previously described [37,38], we used the qBase+ software to 
normalize all qRT-PCR data against multiple stably expressed control genes (information applied in 
respective figure legends). 
4.9. Statistical Analysis 
Results are represented as the mean ± SD. All analyses comprised independent experiments and  
two-way ANOVA, and two-tailed student’s t-tests were performed, as indicated [GraphPad Prism  
(5.0 version) software, La Jolla, CA, USA] to test significant levels. In the animal experiments, data on 
the effect of AngII and ET-1 were obtained from 6–8 and 3–5 animals, respectively. Data not 
following Gaussian distribution, as tested by D’Agostino’s normality test, were subjected to a Log10 
transformation before statistical analysis and normality evidenced to follow Gaussian distribution prior 
to significance tests. Differences were considered to be significant at p < 0.05. 
5. Conclusions  
In conclusion, we found that miR-132 and -212 are increased in AngII-induced hypertension  
in vivo, in organs associated with blood pressure control, which partly mimics the “five miRNA” 
expression signature obtained by AT1R overexpression [19]. Cleary, the in vivo model adds to our 
understanding, as we can narrow down the miRNA changes after AngII, to miR-132 and -212. 
Importantly, our results show that functional inhibition of the AT1R reversed the miR-132 and -212 
expression levels, demonstrating that AngII is responsible for the regulation, possibly via the  
Gαq-dependent pathway. 
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